HTGF, Think.Health Ventures and Business Angels have also supplied funding to Max Planck Institute for Biochemistry mass spectrometry spinout PreOmics.
PreOmics, a Germany-based mass spectrometry sampling technology business based on research from Max Planck Institute for Biochemistry, has obtained €3.3m ($3.8m) in a series A round backed by public-private partnership High-Tech Gründerfonds.
The round was led by Think.Health Ventures with participation from syndicate Business Angels.
Founded in 2016, PreOmics has devised a technology that helps prepare standardised samples for mass spectrometry research so that project teams can improve the chances of achieving robust and reproducible results.
Mass spectrometry is a scientific analysis technique that works by ionising chemical subcategories and then plotting them according to their mass-to-charge ratio.
While the technique has many scientific applications, PreOmics’ sampling kit was originally intended for proteomics research, through which mass spectrometry pinpoints molecules and chemical compounds within a given protein sample.
PreOmics was co-founded by Garwin Pichler and Nils Kulak, then researchers in the proteomics and signal transduction…
